aTyr Pharma is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Our lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause chronic inflammation and progressive fibrosis, or scarring, of the lungs. We are currently investigating efzofitimod in the global Phase 3 EFZO-FIT™ study in patients with pulmonary sarcoidosis, a major form of ILD. This study has completed enrollment and topline data are expected in the third quarter of 2025. We are also conducting the Phase 2 EFZO-CONNECT™ study of efzofitimod in patients with systemic sclerosis (SSc, or scleroderma)-related ILD. Efzofitimod has received U.S., E.U. and Japanese orphan drug designations and U.S. Fast Track Designation for sarcoidosis. Additionally, efzofitimod has received U.S. and E.U. orphan drug designations and U.S. Fast Track designation for SSc. We also have a partnership with Kyorin Pharmaceutical, Co., Ltd., with a total deal value up to $175m, for the development and commercialization of efzofitimod for ILD in Japan. In addition to efzofitimod, we have a pipeline of therapeutic candidates derived from our tRNA synthetase platform targeting inflammation and fibrosis.